









Markets
/
Stocks
/
nasdaq-tech
/

Bio-Techne Corp

TECH

52.700USD

+0.010+0.02%

Close 03/26, 16:00（ET）Quotes delayed by 15 min

7.80BMarket Cap

100.76P/E TTM



Bio-Techne Corp

52.700

+0.010+0.02%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Bio-Techne Corp

Currency: USD Updated: 2026-03-26

Key Insights

Bio-Techne Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 29 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 75.22.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bio-Techne Corp's Score

Industry at a Glance

Industry Ranking

29 / 391

Overall Ranking

108 / 4546

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Bio-Techne Corp Highlights

StrengthsRisks

Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 68.69%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 68.69%.

Overvalued

The company’s latest PE is 100.76, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 172.60M shares, increasing 1.75% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.95K shares of this stock.

Analyst Rating

Based on 17 analysts

Buy

Current Rating

75.221

Target Price

+43.47%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-26

The current financial score of Bio-Techne Corp is 9.02, ranking 19 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 295.88M, representing a year-over-year decrease of 0.39%, while its net profit experienced a year-over-year decrease of 8.93%.

Score

Industry at a Glance

Previous score

9.02

Change



Financials

7.62

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.68

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

9.50

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Bio-Techne Corp's Company Valuation

Currency: USD Updated: 2026-03-26

The current valuation score of Bio-Techne Corp is 4.22, ranking 382 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 100.76, which is 41.84% below the recent high of 142.92 and 66.53% above the recent low of 33.73.

Score

Industry at a Glance

Previous score

4.22

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 29/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-26

The current earnings forecast score of Bio-Techne Corp is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 70.00, with a high of 75.00 and a low of 60.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 17 analysts

Buy

Current Rating

75.221

Target Price

+43.47%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Bio-Techne Corp

TECH

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-26

The current price momentum score of Bio-Techne Corp is 7.08, ranking 127 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 58.42 and the support level at 47.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.00

Change

0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.834

Neutral

RSI(14)

42.236

Neutral

STOCH(KDJ)(9,3,3)

78.191

Buy

ATR(14)

2.279

Low Volatility

CCI(14)

59.714

Neutral

Williams %R

35.367

Buy

TRIX(12,20)

-0.663

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

52.260

Buy

MA10

51.442

Buy

MA20

53.432

Sell

MA50

59.801

Sell

MA100

60.349

Sell

MA200

57.683

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-26

The current institutional shareholding score of Bio-Techne Corp is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 110.32%, representing a quarter-over-quarter increase of 6.57%. The largest institutional shareholder is The Vanguard, holding a total of 17.77M shares, representing 11.36% of shares outstanding, with 3.53% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

17.89M

-2.74%

BlackRock Institutional Trust Company, N.A.

8.79M

-0.08%

State Street Investment Management (US)

5.75M

-1.80%

Wellington Management Company, LLP

5.12M

+349.84%

Geode Capital Management, L.L.C.

4.93M

+21.28%

Atlanta Capital Management Company, L.L.C.

4.94M

+15.06%

Maverick Capital, Ltd.

Star Investors

3.01M

T. Rowe Price Associates, Inc.

Star Investors

3.12M

-63.78%

Invesco Capital Management LLC

Star Investors

3.51M

+8.49%

Risk Assessment

Currency: USD Updated: 2026-03-26

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Bio-Techne Corp is 7.52, ranking 11 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.48. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Bio-Techne Corp’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.